NASDAQ:SANA Sana Biotechnology Q4 2024 Earnings Report $2.94 -0.02 (-0.68%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$2.96 +0.02 (+0.51%) As of 09/25/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Sana Biotechnology EPS ResultsActual EPS-$0.23Consensus EPS -$0.25Beat/MissBeat by +$0.02One Year Ago EPSN/ASana Biotechnology Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASana Biotechnology Announcement DetailsQuarterQ4 2024Date3/17/2025TimeBefore Market OpensConference Call DateMonday, March 17, 2025Conference Call Time5:00PM ETUpcoming EarningsSana Biotechnology's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Sana Biotechnology Earnings Headlines6 'moonshot' biotech stocks that offer big risks, bigger rewardsSeptember 23, 2026 | msn.comSana Biotechnology (SANA)September 23, 2026 | es.investing.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade. | The Oxford Club (Ad)Sana Biotechnology, Inc. (NASDAQ:SANA) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 20, 2026 | americanbankingnews.comSana Biotechnology, Inc. (SANA) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks TranscriptSeptember 15, 2026 | seekingalpha.comSana Biotechnology op Morgan Stanley conferentie: focus op diabetesSeptember 15, 2026 | nl.investing.comSee More Sana Biotechnology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sana Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sana Biotechnology and other key companies, straight to your email. Email Address About Sana BiotechnologySana Biotechnology (NASDAQ:SANA) is a clinical-stage biotechnology company focused on developing engineered cells and gene therapies for the treatment of serious diseases. The company’s approach is designed to create therapeutic cells that can be delivered to patients without requiring individualized manufacturing, potentially broadening access to cell-based medicines. Sana is developing technologies intended to address key challenges in cell and gene therapy, including immune rejection, targeted delivery of genetic material and the production of engineered cells at scale. Its research programs have included cell therapies for oncology and autoimmune diseases, as well as approaches involving induced pluripotent stem cells and allogeneic, or donor-derived, therapeutic cells. Founded in 2018 and headquartered in Seattle, Washington, Sana became a publicly traded company on the Nasdaq under the symbol SANA in 2021. The company’s operations are primarily focused on research and clinical development, with programs being advanced through clinical studies and other development activities. Sana has been led by Chief Executive Officer Steve Harr, who has experience in the biotechnology and pharmaceutical industries.View Sana Biotechnology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/25Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin SettlementSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
